18F-FET-bAG-TOCA

**18F-FET-bAG-TOCA** is a fluorine-18 (^18F) labeled somatostatin analog radioconjugate (specifically, a [^18F]fluoroethyl-triazole-[Tyr3]-octreotate derivative) developed for positron emission tomography (PET) imaging. Its mechanism of action is high-affinity, selective binding to somatostatin receptor type 2 (SSTR2), particularly expressed in neuroendocrine tumors (NETs), enabling sensitive and specific imaging of NET lesions. The agent demonstrates favorable dosimetry, rapid clearance from non-target organs via hepato-biliary and renal excretion, and high tumor uptake with high tumor/background contrast. Clinical trials indicate safety and potential in localizing tumors and differentiating active vasculitis from atherosclerosis. It has improved radiochemical purity and clinical utility compared to older radiotracers like ^68Ga-DOTATATE, and is suitable for late imaging protocols. The drug is being evaluated as a noninferior alternative to existing SSTR-targeted radiotracers for diagnostic imaging in NETs and other indications such as large vessel vasculitis[1][2][3][4][5].

Other names

[^18F]fluoroethyl-triazole-[Tyr3]-octreotate[18F]fluoroethyltriazole[Tyr3]Octreotate